Beyond mRNA Market Likely to Surpass USD 25.5 Billion by 2035

Buy Now

A significant study discovering the market avenues on, “Beyond mRNA Market Size, Share & Trends Analysis Report by Product Type (Prophylactic Vaccines, Therapeutic Vaccines, Protein Replacement Therapeutics, Gene Editing & Modulation), Disease Application, Delivery System, Route of Administration, mRNA Modification Technology, Target Cell, End-Users and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A holistic view of the market pathways in beyond mRNA market underscores revenue acceleration through three key levers scalable product line extensions, high‑maturity strategic partnerships

Global Beyond mRNA Market Forecast 2035:

According to the report, the global beyond mRNA market is likely to grow from USD 12.8 Billion in 2025 to USD 25.5 Billion in 2035 at a highest CAGR of 7.1% during the time period. The expansion of beyond mRNA market is mainly attributed to the continuous evolution of next generation modalities such as circular RNA, self-amplifying RNA and antisense oligonucleotide which are offering improved scalability, durability and precision in therapeutics beyond conventional mRNA platforms. The growing demand for next generation therapies in oncology, rare genetic and infectious diseases is accelerating the adoption. Increasing investments in RNA advancements, specifically for neurological disorders, cancer immunotherapy, metabolic illness is fueling the pipeline of novel candidates and clinical programs.

Advances in synthetic biology, AI- driven designs, lipid-nanoparticle based innovations are improving efficiency and reducing the costs, thereby broadening RNA’s therapeutic potential and accessibility cross both large pharmaceutical companies and emerging biotech players. Moreover, the expanding applications of beyond mRNA therapeutics in personal medicines, gene modulation therapies and vaccines are further contributing to the growth.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global beyond m RNA Market

The beyond mRNA magnets market is also driven by the growing interest in personalized medicine, where next generation RNA modalities or combining with immune checkpoint inhibitors are designed to match individual genetic and disease profile. For instance, Moderna and Merck’s investigational personalized mRNA cancer vaccine mRNA-4157/V940, in combination with KEYTRUDA, received an FDA breakthrough therapy designation for high-risk melanoma. In order to grow up the development of more focused and efficient treatments, pharmaceutical companies and research institutes are rapidly adopting these therapies, which allows for precise control of gene expression and durable protein creation personalized for each patient.

The major limitation, beyond mRNA platforms often require for specific delivery sectors, specialized bioprocessing tools and personalized raw materials, which are not completely standardized. This results in the high production costs and supply vulnerabilities, reliance on specialized suppliers and difficulties scaling production to commercial volumes.

In addition to mRNA technologies, regenerative medicine is being pushed to the next level by the use of RNA encoding growth factors and therapeutic proteins to the injured tissue. For instance, a team of scientists at the University of Wisconsin-Madison has invented a promising approach to the treatment of osteoarthritis with the help of therapeutic blood clots that require activation by messenger RNA. These new treatments can speed up the healing of tissues, enhance the healing of patients, and create new markets with high value in the treatment of cardiac, orthopedic, and degenerative diseases.

Expansion of Global Beyond mRNA Market

“Innovation in lipid nanoparticle technology and pharma demand propel the global Beyond mRNA market expansion”

For instance, in January 2025, eTheRNA Immunotherapies, a pioneer in mRNA and lipid nanoparticle (LNP) technologies signed a strategic multi-target agreement with Dropshot Therapeutics (US) up to USD 950 million. The collaboration would combine the proprietary mRNA and LNP delivery systems of eTheRNA with Dropshot to develop innovative RNA-based therapeutics by leveraging the expertise it has in cardiac and renal disease. This partnership will help develop several drugs candidates within a short time period to go through preclinical testing to clinical trials which mention the role of strategic partnerships in accelerating innovation and broadening the therapeutic utility of beyond mRNA platforms across various indications.
Pharma-biotechs continue to invest heavily in beyond mRNA technologies with an aim to diversify their therapeutic pipelines and improving capabilities of precision medicine. For instance, in 2025, AbbVie and ADARx Pharmaceuticals entered into an agreement in the form of a partnership and license option agreement to create siRNA therapies, which target oncology, neuroscience and immunology. This partnership demonstrates AbbVie’s intention to expand its range of RNA treatments and ADARx’s proficiency in late clinical stage RNA technologies.

Regional Analysis of Global Beyond mRNA Market

The beyond mRNA market in North America has the strongest demand, Because of the large number of biotech hubs, pharmaceutical companies, and cutting-edge research institutions actively researching next-generation RNA treatments. Companies are on the forefront in the development of next generation self-amplifying RNA, circular RNA and the use of RNA delivery technology. Also, extensive network of clinical trial locations and manufacturing plants in North America enable rapid research, testing and introduction of Beyond mRNA therapies. For instance, on 2025, Circurna and GATC Health announced a collaboration, to boost the design and optimization of their circular RNA therapeutic platform through the use of AI-based discovery tools. This advancement strengthens the North America’s leadership in beyond mRNA innovation, reducing R&D timelines and fueling funding in RNA based therapeutics.
The rapid expansion of biotech centers, increased pharmaceutical R&D and growing investments in next-generation RNA technologies propel the Asia-Pacific region to the forefront of the beyond mRNA market growth Through the development of RNA focused research facilities, government financing initiatives and support for clinical trials, nations like India, Japan and China are enhancing their capabilities in RNA treatments. The advancements Asia-Pacific’s growth as an important factor for the beyond mRNA market’s expansion, positioning at the cutting edge for the development of vaccines and next generation RNA therapies.

Prominent players operating in the global beyond mRNA market are Acuitas Therapeutics, Alnylam Pharmaceuticals, Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., eTheRNA (part of Boehringer Ingelheim), Ethris GmbH, Genevant Sciences, Immorna Biotherapeutics, Kernal Biologic, Moderna, Inc., Pfizer Inc., Precision NanoSystems, Providence Therapeutics, Sanofi, Stemirna Therapeutics, Strand Therapeutic, Suzhou Abogen Bioscience, and Other Key Players.

The global Beyond mRNA market has been segmented as follows:

Global beyond mRNA Market Analysis, by Product Type

Prophylactic Vaccines
Therapeutic Vaccines
Protein Replacement Therapeutics
Gene Editing & Modulation

Global Beyond mRNA Market Analysis, by Application

Oncology
Infectious Diseases
Rare Genetic Diseases
- Monogenic disorders
- Metabolic diseases
- Neurodegenerative conditions
- Others
Autoimmune Disorders
- Multiple sclerosis
- Rheumatoid arthritis
- Type 1 diabetes
- Others
Cardiovascular Diseases
Respiratory Diseases
Neurological Disorders
Metabolic Disorders

Global Beyond mRNA Market Analysis, by delivery system

Lipid Nanoparticles (LNPs)
- Ionizable LNPs
- Targeted LNPs
- Tissue-specific LNPs
Polymeric Nanoparticles
- PLGA-based systems
- Chitosan-based carriers
- PEI-based delivery systems
Viral Vector Systems
- Adeno-associated virus (AAV)
- Lentiviral vectors
- Modified vaccinia virus
Physical Delivery Methods
- Electroporation
- Microinjection
- Gene gun delivery
Alternative Delivery Platforms
- Exosome-based delivery
- Cell-penetrating peptides
- Implantable delivery devices

Global Beyond mRNA Market Analysis, by route of administration

Intramuscular Injection

Intravenous Administration
Subcutaneous Injection
Inhalation Delivery
Topical/Dermal Application
Oral Delivery
Intranasal Administration
Intrathecal Delivery

Global Beyond mRNA Market Analysis, by technology

Pseudouridine-Modified mRNA

5-Methylcytidine Modified mRNA
Cap Structure Modifications
Codon-Optimized mRNA
Self-Amplifying RNA (saRNA)
Circular RNA (circRNA)
Chemically Modified mRNA

Global Beyond mRNA Market Analysis, by target cell

Immune System Targeting
- Dendritic cells
- T lymphocytes
- B lymphocytes
- Macrophages
Organ-Specific Targeting
- Liver-targeted delivery
- Brain/CNS targeting
- Lung-specific delivery
- Muscle-targeted systems
Tumor-Targeted Delivery
- Cancer cell-specific targeting
- Tumor microenvironment modulation
Stem Cell Targeting
- Hematopoietic stem cells
- Mesenchymal stem cells

Global Beyond mRNA Market Analysis, by End Users

Pharmaceutical & Biotechnology Industry
- Pharma Companies
- Biotech Startups & Mid-Caps
- Contract Development & Manufacturing Organizations (CDMOs)
Healthcare Delivery Systems
- Hospitals & Health Systems
- Specialty Treatment Centers
- Point-of-Care Facilities

Research & Academic Institutions

Global Beyond mRNA Market Analysis, by Region

North America
Europe
Asia Pacific
Middle East
Africa
South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
  - 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
  - 1.6.1. Open Sources
  - 1.6.2. Paid Databases
  - 1.6.3. Associations
- 1.7. Primary Research
  - 1.7.1. Primary Sources
  - 1.7.2. Primary Interviews with Stakeholders across Ecosystem
2. Executive Summary
- 2.1. Global Beyond mRNA Market Outlook
  - 2.1.1. Beyond mRNA Market Size (Value - US$ Bn), and Forecasts, 2021-2035
  - 2.1.2. Compounded Annual Growth Rate Analysis
  - 2.1.3. Growth Opportunity Analysis
  - 2.1.4. Segmental Share Analysis
  - 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
  - 2.5.1. Customer/ End-use Industry Assessment
  - 2.5.2. Growth Opportunity Data, 2025-2035
    - 2.5.2.1. Regional Data
    - 2.5.2.2. Country Data
    - 2.5.2.3. Segmental Data
  - 2.5.3. Identification of Potential Market Spaces
  - 2.5.4. GAP Analysis
  - 2.5.5. Potential Attractive Price Points
  - 2.5.6. Prevailing Market Risks & Challenges
  - 2.5.7. Preferred Sales & Marketing Strategies
  - 2.5.8. Key Recommendations and Analysis
  - 2.5.9. A Way Forward
3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
  - 3.1.1. Healthcare & PharmaceuticalIndustry Ecosystem Analysis
  - 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
  - 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trade Analysis
  - 3.4.1. Import & Export Analysis, 2025
  - 3.4.2. Top Importing Countries
  - 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
  - 3.5.1. Manufacturer
    - 3.5.1.1. Based on the component & Raw material
  - 3.5.2. Supply Chain
  - 3.5.3. End Consumer
- 3.6. Raw Material Analysis
4. Market Overview
- 4.1. Market Dynamics
  - 4.1.1. Drivers
    - 4.1.1.1. Rising demand for RNA-based therapeutics in oncology and rare diseases
    - 4.1.1.2. Technological advancements in RNA delivery and stability
    - 4.1.1.3. Increasing investment and funding in RNA innovation
  - 4.1.2. Restraints
    - 4.1.2.1. Complex manufacturing and purification processes
    - 4.1.2.2. High production costs limiting scalability
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
  - 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
  - 4.3.2. Tariffs and Standards
  - 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global Beyond mRNA Market Demand
  - 4.7.1. Historical Market Size - in Value (US$ Bn), 2020-2024
  - 4.7.2. Current and Future Market Size - in Value (US$ Bn), 2025–2035
    - 4.7.2.1. Y-o-Y Growth Trends
    - 4.7.2.2. Absolute $ Opportunity Assessment
5. Competition Landscape
- 5.1. Competition structure
  - 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
  - 5.2.1. Global Company Market Share
  - 5.2.2. By Region
    - 5.2.2.1. North America
    - 5.2.2.2. Europe
    - 5.2.2.3. Asia Pacific
    - 5.2.2.4. Middle East
    - 5.2.2.5. Africa
    - 5.2.2.6. South America
- 5.3. Product Comparison Matrix
  - 5.3.1. Specifications
  - 5.3.2. Market Positioning
  - 5.3.3. Pricing
6. Global Beyond mRNA Market Analysis, by Product Type
- 6.1. Key Segment Analysis
- 6.2. Beyond mRNA Market Size (Value - US$ Bn), Analysis, and Forecasts, By Product Type, 2021-2035
  - 6.2.1. Prophylactic Vaccines
  - 6.2.2. Therapeutic Vaccines
  - 6.2.3. Protein Replacement Therapeutics
  - 6.2.4. Gene Editing & Modulation
  - 6.2.5. Oligonucleotide therapeutics/ Antisense & RNAi
  - 6.2.6. Others
7. Global Beyond mRNA Market Analysis, by Disease Application
- 7.1. Key Segment Analysis
- 7.2. Beyond mRNA Market Size (Value - US$ Bn), Analysis, and Forecasts, By Disease Application, 2021-2035
  - 7.2.1. Oncology
  - 7.2.2. Infectious Diseases
  - 7.2.3. Rare Genetic Diseases
    - 7.2.3.1. Monogenic disorders
    - 7.2.3.2. Metabolic diseases
    - 7.2.3.3. Neurodegenerative conditions
    - 7.2.3.4. Others
  - 7.2.4. Autoimmune Disorders
    - 7.2.4.1. Multiple sclerosis
    - 7.2.4.2. Rheumatoid arthritis
    - 7.2.4.3. Type 1 diabetes
    - 7.2.4.4. Others
  - 7.2.5. Cardiovascular Diseases
  - 7.2.6. Respiratory Diseases
  - 7.2.7. Neurological Disorders
  - 7.2.8. Metabolic Disorders
  - 7.2.9. Others
8. Global Beyond mRNA Market Analysis and Forecasts, by Delivery System
- 8.1. Key Findings
- 8.2. Beyond mRNA Market Size (Value - US$ Mn), Analysis, and Forecasts, by Delivery System, 2021-2035
  - 8.2.1. Lipid Nanoparticles (LNPs)
    - 8.2.1.1. Ionizable LNPs
    - 8.2.1.2. Targeted LNPs
    - 8.2.1.3. Tissue-specific LNPs
  - 8.2.2. Polymeric Nanoparticles
    - 8.2.2.1. PLGA-based systems
    - 8.2.2.2. Chitosan-based carriers
    - 8.2.2.3. PEI-based delivery systems
  - 8.2.3. Viral Vector Systems
    - 8.2.3.1. Adeno-associated virus (AAV)
    - 8.2.3.2. Lentiviral vectors
    - 8.2.3.3. Modified vaccinia virus
  - 8.2.4. Physical Delivery Methods
    - 8.2.4.1. Electroporation
    - 8.2.4.2. Microinjection
    - 8.2.4.3. Gene gun delivery
  - 8.2.5. Alternative Delivery Platforms
    - 8.2.5.1. Exosome-based delivery
    - 8.2.5.2. Cell-penetrating peptides
    - 8.2.5.3. Implantable delivery devices
9. Global Beyond mRNA Market Analysis and Forecasts, by Route of Administration
- 9.1. Key Findings
- 9.2. Beyond mRNA Market Size (Vo Value - US$ Mn), Analysis, and Forecasts, By Route of Administration, 2021-2035
  - 9.2.1. Intramuscular Injection
  - 9.2.2. Intravenous Administration
  - 9.2.3. Subcutaneous Injection
  - 9.2.4. Inhalation Delivery
  - 9.2.5. Topical/Dermal Application
  - 9.2.6. Oral Delivery
  - 9.2.7. Intranasal Administration
  - 9.2.8. Intrathecal Delivery
10. Global Beyond mRNA Market Analysis and Forecasts, by mRNA Modification Technology
- 10.1. Key Findings
- 10.2. Beyond mRNA Market Size (Value - US$ Mn), Analysis, and Forecasts, By mRNA Modification Technology, 2021-2035
  - 10.2.1. Pseudouridine-Modified mRNA
  - 10.2.2. 5-Methylcytidine Modified mRNA
  - 10.2.3. Cap Structure Modifications
  - 10.2.4. Codon-Optimized mRNA
  - 10.2.5. Self-Amplifying RNA (saRNA)
  - 10.2.6. Circular RNA (circRNA)
  - 10.2.7. Chemically Modified mRNA
  - 10.2.8. Others
11. Global Beyond mRNA Market Analysis and Forecasts, by Target Cell
- 11.1. Key Findings
- 11.2. Beyond mRNA Market Size (Value - US$ Mn), Analysis, and Forecasts, By Target Cell, 2021-2035
  - 11.2.1. Immune System Targeting
    - 11.2.1.1. Dendritic cells
    - 11.2.1.2. T lymphocytes
    - 11.2.1.3. B lymphocytes
    - 11.2.1.4. Macrophages
  - 11.2.2. Organ-Specific Targeting
    - 11.2.2.1. Liver-targeted delivery
    - 11.2.2.2. Brain/CNS targeting
    - 11.2.2.3. Lung-specific delivery
    - 11.2.2.4. Muscle-targeted systems
  - 11.2.3. Tumor-Targeted Delivery
    - 11.2.3.1. Cancer cell-specific targeting
    - 11.2.3.2. Tumor microenvironment modulation
  - 11.2.4. Stem Cell Targeting
    - 11.2.4.1. Hematopoietic stem cells
    - 11.2.4.2. Mesenchymal stem cells
12. Global Beyond mRNA Market Analysis and Forecasts, By End-users
- 12.1. Key Findings
- 12.2. Beyond mRNA Market Size (Value - US$ Mn), Analysis, and Forecasts, By End-users, 2021-2035
  - 12.2.1. Pharmaceutical & Biotechnology Industry
    - 12.2.1.1. Pharma Companies
    - 12.2.1.2. Biotech Startups & Mid-Caps
    - 12.2.1.3. Contract Development & Manufacturing Organizations (CDMOs)
  - 12.2.2. Healthcare Delivery Systems
    - 12.2.2.1. Hospitals & Health Systems
    - 12.2.2.2. Specialty Treatment Centers
    - 12.2.2.3. Point-of-Care Facilities
  - 12.2.3. Research & Academic Institutions
13. Global Beyond mRNA Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. Beyond mRNA Market Size (Value - US$ Mn), Analysis, and Forecasts, by Region, 2021-2035
  - 13.2.1. North America
  - 13.2.2. Europe
  - 13.2.3. Asia Pacific
  - 13.2.4. Middle East
  - 13.2.5. Africa
  - 13.2.6. South America
14. North America Beyond mRNA Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America Beyond mRNA Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 14.3.1. Product Type
  - 14.3.2. Disease Application
  - 14.3.3. Delivery System
  - 14.3.4. Route of Administration
  - 14.3.5. mRNA Modification Technology
  - 14.3.6. Target Cell
  - 14.3.7. End-Users
  - 14.3.8. Country
    - 14.3.8.1. USA
    - 14.3.8.2. Canada
    - 14.3.8.3. Mexico
- 14.4. USA Beyond mRNA Market
  - 14.4.1. Country Segmental Analysis
  - 14.4.2. Product Type
  - 14.4.3. Disease Application
  - 14.4.4. Delivery System
  - 14.4.5. Route of Administration
  - 14.4.6. mRNA Modification Technology
  - 14.4.7. Target Cell
  - 14.4.8. End-Users
- 14.5. Canada Beyond mRNA Market
  - 14.5.1. Country Segmental Analysis
  - 14.5.2. Product Type
  - 14.5.3. Disease Application
  - 14.5.4. Delivery System
  - 14.5.5. Route of Administration
  - 14.5.6. mRNA Modification Technology
  - 14.5.7. Target Cell
  - 14.5.8. End-Users
- 14.6. Mexico Beyond mRNA Market
  - 14.6.1. Country Segmental Analysis
  - 14.6.2. Product Type
  - 14.6.3. Disease Application
  - 14.6.4. Delivery System
  - 14.6.5. Route of Administration
  - 14.6.6. mRNA Modification Technology
  - 14.6.7. Target Cell
  - 14.6.8. End-Users
15. Europe Beyond mRNA Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe Beyond mRNA Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 15.3.1. Product Type
  - 15.3.2. Disease Application
  - 15.3.3. Delivery System
  - 15.3.4. Route of Administration
  - 15.3.5. mRNA Modification Technology
  - 15.3.6. Target Cell
  - 15.3.7. End-Users
  - 15.3.8. Country
    - 15.3.8.1. Germany
    - 15.3.8.2. United Kingdom
    - 15.3.8.3. France
    - 15.3.8.4. Italy
    - 15.3.8.5. Spain
    - 15.3.8.6. Netherlands
    - 15.3.8.7. Nordic Countries
    - 15.3.8.8. Poland
    - 15.3.8.9. Russia & CIS
    - 15.3.8.10. Rest of Europe
- 15.4. Germany Beyond mRNA Market
  - 15.4.1. Country Segmental Analysis
  - 15.4.2. Product Type
  - 15.4.3. Disease Application
  - 15.4.4. Delivery System
  - 15.4.5. Route of Administration
  - 15.4.6. mRNA Modification Technology
  - 15.4.7. Target Cell
  - 15.4.8. End-Users
- 15.5. United Kingdom Beyond mRNA Market
  - 15.5.1. Country Segmental Analysis
  - 15.5.2. Product Type
  - 15.5.3. Disease Application
  - 15.5.4. Delivery System
  - 15.5.5. Route of Administration
  - 15.5.6. mRNA Modification Technology
  - 15.5.7. Target Cell
  - 15.5.8. End-Users
- 15.6. France Beyond mRNA Market
  - 15.6.1. Country Segmental Analysis
  - 15.6.2. Product Type
  - 15.6.3. Disease Application
  - 15.6.4. Delivery System
  - 15.6.5. Route of Administration
  - 15.6.6. mRNA Modification Technology
  - 15.6.7. Target Cell
  - 15.6.8. End-Users
- 15.7. Italy Beyond mRNA Market
  - 15.7.1. Country Segmental Analysis
  - 15.7.2. Product Type
  - 15.7.3. Disease Application
  - 15.7.4. Delivery System
  - 15.7.5. Route of Administration
  - 15.7.6. mRNA Modification Technology
  - 15.7.7. Target Cell
  - 15.7.8. End-Users
- 15.8. Spain Beyond mRNA Market
  - 15.8.1. Country Segmental Analysis
  - 15.8.2. Product Type
  - 15.8.3. Disease Application
  - 15.8.4. Delivery System
  - 15.8.5. Route of Administration
  - 15.8.6. mRNA Modification Technology
  - 15.8.7. Target Cell
  - 15.8.8. End-Users
- 15.9. Netherlands Beyond mRNA Market
  - 15.9.1. Country Segmental Analysis
  - 15.9.2. Product Type
  - 15.9.3. Disease Application
  - 15.9.4. Delivery System
  - 15.9.5. Route of Administration
  - 15.9.6. mRNA Modification Technology
  - 15.9.7. Target Cell
  - 15.9.8. End-Users
- 15.10. Nordic Countries Beyond mRNA Market
  - 15.10.1. Country Segmental Analysis
  - 15.10.2. Product Type
  - 15.10.3. Disease Application
  - 15.10.4. Delivery System
  - 15.10.5. Route of Administration
  - 15.10.6. mRNA Modification Technology
  - 15.10.7. Target Cell
  - 15.10.8. End-Users
- 15.11. Poland Beyond mRNA Market
  - 15.11.1. Country Segmental Analysis
  - 15.11.2. Product Type
  - 15.11.3. Disease Application
  - 15.11.4. Delivery System
  - 15.11.5. Route of Administration
  - 15.11.6. mRNA Modification Technology
  - 15.11.7. Target Cell
  - 15.11.8. End-Users
- 15.12. Russia & CIS Beyond mRNA Market
  - 15.12.1. Country Segmental Analysis
  - 15.12.2. Product Type
  - 15.12.3. Disease Application
  - 15.12.4. Delivery System
  - 15.12.5. Route of Administration
  - 15.12.6. mRNA Modification Technology
  - 15.12.7. Target Cell
  - 15.12.8. End-Users
- 15.13. Rest of Europe Beyond mRNA Market
  - 15.13.1. Country Segmental Analysis
  - 15.13.2. Product Type
  - 15.13.3. Disease Application
  - 15.13.4. Delivery System
  - 15.13.5. Route of Administration
  - 15.13.6. mRNA Modification Technology
  - 15.13.7. Target Cell
  - 15.13.8. End-Users
16. Asia Pacific Beyond mRNA Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. East Asia Beyond mRNA Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 16.3.1. Product Type
  - 16.3.2. Product Type
  - 16.3.3. Disease Application
  - 16.3.4. Delivery System
  - 16.3.5. Route of Administration
  - 16.3.6. mRNA Modification Technology
  - 16.3.7. Target Cell
  - 16.3.8. End-Users
  - 16.3.9. Country
    - 16.3.9.1. China
    - 16.3.9.2. India
    - 16.3.9.3. Japan
    - 16.3.9.4. South Korea
    - 16.3.9.5. Australia and New Zealand
    - 16.3.9.6. Indonesia
    - 16.3.9.7. Malaysia
    - 16.3.9.8. Thailand
    - 16.3.9.9. Vietnam
    - 16.3.9.10. Rest of Asia Pacific
- 16.4. China Beyond mRNA Market
  - 16.4.1. Country Segmental Analysis
  - 16.4.2. Product Type
  - 16.4.3. Disease Application
  - 16.4.4. Delivery System
  - 16.4.5. Route of Administration
  - 16.4.6. mRNA Modification Technology
  - 16.4.7. Target Cell
  - 16.4.8. End-Users
- 16.5. India Beyond mRNA Market
  - 16.5.1. Country Segmental Analysis
  - 16.5.2. Product Type
  - 16.5.3. Disease Application
  - 16.5.4. Delivery System
  - 16.5.5. Route of Administration
  - 16.5.6. mRNA Modification Technology
  - 16.5.7. Target Cell
  - 16.5.8. End-Users
- 16.6. Japan Beyond mRNA Market
  - 16.6.1. Country Segmental Analysis
  - 16.6.2. Product Type
  - 16.6.3. Disease Application
  - 16.6.4. Delivery System
  - 16.6.5. Route of Administration
  - 16.6.6. mRNA Modification Technology
  - 16.6.7. Target Cell
  - 16.6.8. End-Users
- 16.7. South Korea Beyond mRNA Market
  - 16.7.1. Country Segmental Analysis
  - 16.7.2. Product Type
  - 16.7.3. Disease Application
  - 16.7.4. Delivery System
  - 16.7.5. Route of Administration
  - 16.7.6. mRNA Modification Technology
  - 16.7.7. Target Cell
  - 16.7.8. End-Users
- 16.8. Australia and New Zealand Beyond mRNA Market
  - 16.8.1. Country Segmental Analysis
  - 16.8.2. Product Type
  - 16.8.3. Disease Application
  - 16.8.4. Delivery System
  - 16.8.5. Route of Administration
  - 16.8.6. mRNA Modification Technology
  - 16.8.7. Target Cell
  - 16.8.8. End-Users
- 16.9. Indonesia Beyond mRNA Market
  - 16.9.1. Country Segmental Analysis
  - 16.9.2. Product Type
  - 16.9.3. Disease Application
  - 16.9.4. Delivery System
  - 16.9.5. Route of Administration
  - 16.9.6. mRNA Modification Technology
  - 16.9.7. Target Cell
  - 16.9.8. End-Users
- 16.10. Malaysia Beyond mRNA Market
  - 16.10.1. Country Segmental Analysis
  - 16.10.2. Product Type
  - 16.10.3. Disease Application
  - 16.10.4. Delivery System
  - 16.10.5. Route of Administration
  - 16.10.6. mRNA Modification Technology
  - 16.10.7. Target Cell
  - 16.10.8. End-Users
- 16.11. Thailand Beyond mRNA Market
  - 16.11.1. Country Segmental Analysis
  - 16.11.2. Product Type
  - 16.11.3. Disease Application
  - 16.11.4. Delivery System
  - 16.11.5. Route of Administration
  - 16.11.6. mRNA Modification Technology
  - 16.11.7. Target Cell
  - 16.11.8. End-Users
- 16.12. Vietnam Beyond mRNA Market
  - 16.12.1. Country Segmental Analysis
  - 16.12.2. Product Type
  - 16.12.3. Disease Application
  - 16.12.4. Delivery System
  - 16.12.5. Route of Administration
  - 16.12.6. mRNA Modification Technology
  - 16.12.7. Target Cell
  - 16.12.8. End-Users
- 16.13. Rest of Asia Pacific Beyond mRNA Market
  - 16.13.1. Country Segmental Analysis
  - 16.13.2. Product Type
  - 16.13.3. Disease Application
  - 16.13.4. Delivery System
  - 16.13.5. Route of Administration
  - 16.13.6. mRNA Modification Technology
  - 16.13.7. Target Cell
  - 16.13.8. End-Users
17. Middle East Beyond mRNA Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East Beyond mRNA Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 17.3.1. Product Type
  - 17.3.2. Disease Application
  - 17.3.3. Delivery System
  - 17.3.4. Route of Administration
  - 17.3.5. mRNA Modification Technology
  - 17.3.6. Target Cell
  - 17.3.7. End-Users
  - 17.3.8. Country
    - 17.3.8.1. Turkey
    - 17.3.8.2. UAE
    - 17.3.8.3. Saudi Arabia
    - 17.3.8.4. Israel
    - 17.3.8.5. Rest of Middle East
- 17.4. Turkey Beyond mRNA Market
  - 17.4.1. Country Segmental Analysis
  - 17.4.2. Product Type
  - 17.4.3. Disease Application
  - 17.4.4. Delivery System
  - 17.4.5. Route of Administration
  - 17.4.6. mRNA Modification Technology
  - 17.4.7. Target Cell
  - 17.4.8. End-Users
- 17.5. UAE Beyond mRNA Market
  - 17.5.1. Country Segmental Analysis
  - 17.5.2. Product Type
  - 17.5.3. Disease Application
  - 17.5.4. Delivery System
  - 17.5.5. Route of Administration
  - 17.5.6. mRNA Modification Technology
  - 17.5.7. Target Cell
  - 17.5.8. End-Users
- 17.6. Saudi Arabia Beyond mRNA Market
  - 17.6.1. Country Segmental Analysis
  - 17.6.2. Product Type
  - 17.6.3. Disease Application
  - 17.6.4. Delivery System
  - 17.6.5. Route of Administration
  - 17.6.6. mRNA Modification Technology
  - 17.6.7. Target Cell
  - 17.6.8. End-Users
- 17.7. Israel Beyond mRNA Market
  - 17.7.1. Country Segmental Analysis
  - 17.7.2. Product Type
  - 17.7.3. Disease Application
  - 17.7.4. Delivery System
  - 17.7.5. Route of Administration
  - 17.7.6. mRNA Modification Technology
  - 17.7.7. Target Cell
  - 17.7.8. End-Users
- 17.8. Rest of Middle East Beyond mRNA Market
  - 17.8.1. Country Segmental Analysis
  - 17.8.2. Product Type
  - 17.8.3. Disease Application
  - 17.8.4. Delivery System
  - 17.8.5. Route of Administration
  - 17.8.6. mRNA Modification Technology
  - 17.8.7. Target Cell
  - 17.8.8. End-Users
18. Africa Beyond mRNA Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa Beyond mRNA Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 18.3.1. Product Type
  - 18.3.2. Disease Application
  - 18.3.3. Delivery System
  - 18.3.4. Route of Administration
  - 18.3.5. mRNA Modification Technology
  - 18.3.6. Target Cell
  - 18.3.7. End-Users
  - 18.3.8. Country
    - 18.3.8.1. South Africa
    - 18.3.8.2. Egypt
    - 18.3.8.3. Nigeria
    - 18.3.8.4. Algeria
    - 18.3.8.5. Rest of Africa
- 18.4. South Africa Beyond mRNA Market
  - 18.4.1. Country Segmental Analysis
  - 18.4.2. Product Type
  - 18.4.3. Disease Application
  - 18.4.4. Delivery System
  - 18.4.5. Route of Administration
  - 18.4.6. mRNA Modification Technology
  - 18.4.7. Target Cell
  - 18.4.8. End-Users
- 18.5. Egypt Beyond mRNA Market
  - 18.5.1. Country Segmental Analysis
  - 18.5.2. Product Type
  - 18.5.3. Disease Application
  - 18.5.4. Delivery System
  - 18.5.5. Route of Administration
  - 18.5.6. mRNA Modification Technology
  - 18.5.7. Target Cell
  - 18.5.8. End-Users
- 18.6. Nigeria Beyond mRNA Market
  - 18.6.1. Country Segmental Analysis
  - 18.6.2. Product Type
  - 18.6.3. Disease Application
  - 18.6.4. Delivery System
  - 18.6.5. Route of Administration
  - 18.6.6. mRNA Modification Technology
  - 18.6.7. Target Cell
  - 18.6.8. End-Users
- 18.7. Algeria Beyond mRNA Market
  - 18.7.1. Country Segmental Analysis
  - 18.7.2. Product Type
  - 18.7.3. Disease Application
  - 18.7.4. Delivery System
  - 18.7.5. Route of Administration
  - 18.7.6. mRNA Modification Technology
  - 18.7.7. Target Cell
  - 18.7.8. End-Users
- 18.8. Rest of Africa Beyond mRNA Market
  - 18.8.1. Country Segmental Analysis
  - 18.8.2. Product Type
  - 18.8.3. Disease Application
  - 18.8.4. Delivery System
  - 18.8.5. Route of Administration
  - 18.8.6. mRNA Modification Technology
  - 18.8.7. Target Cell
  - 18.8.8. End-Users
19. South America Beyond mRNA Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Central and South Africa Beyond mRNA Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 19.3.1. Product Type
  - 19.3.2. Disease Application
  - 19.3.3. Delivery System
  - 19.3.4. Route of Administration
  - 19.3.5. mRNA Modification Technology
  - 19.3.6. Target Cell
  - 19.3.7. End-Users
  - 19.3.8. Country
    - 19.3.8.1. Brazil
    - 19.3.8.2. Argentina
    - 19.3.8.3. Rest of South America
- 19.4. Brazil Beyond mRNA Market
  - 19.4.1. Country Segmental Analysis
  - 19.4.2. Product Type
  - 19.4.3. Disease Application
  - 19.4.4. Delivery System
  - 19.4.5. Route of Administration
  - 19.4.6. mRNA Modification Technology
  - 19.4.7. Target Cell
  - 19.4.8. End-Users
- 19.5. Argentina Beyond mRNA Market
  - 19.5.1. Country Segmental Analysis
  - 19.5.2. Product Type
  - 19.5.3. Disease Application
  - 19.5.4. Delivery System
  - 19.5.5. Route of Administration
  - 19.5.6. mRNA Modification Technology
  - 19.5.7. Target Cell
  - 19.5.8. End-Users
- 19.6. Rest of South America Beyond mRNA Market
  - 19.6.1. Country Segmental Analysis
  - 19.6.2. Product Type
  - 19.6.3. Disease Application
  - 19.6.4. Delivery System
  - 19.6.5. Route of Administration
  - 19.6.6. mRNA Modification Technology
  - 19.6.7. Target Cell
  - 19.6.8. End-Users
20. Key Players/ Company Profile
- 20.1. Acuitas Therapeutics
  - 20.1.1. Company Details/ Overview
  - 20.1.2. Company Financials
  - 20.1.3. Key Customers and Competitors
  - 20.1.4. Business/ Industry Portfolio
  - 20.1.5. Product Portfolio/ Specification Details
  - 20.1.6. Pricing Data
  - 20.1.7. Strategic Overview
  - 20.1.8. Recent Developments
- 20.2. Alnylam Pharmaceuticals
- 20.3. Arcturus Therapeutics Holdings Inc.
- 20.4. BioNTech SE
- 20.5. CureVac N.V.
- 20.6. eTheRNA (part of Boehringer Ingelheim)
- 20.7. Ethris GmbH
- 20.8. Genevant Sciences
- 20.9. Immorna Biotherapeutics
- 20.10. Kernal Biologic
- 20.11. Moderna, Inc.
- 20.12. Pfizer Inc.
- 20.13. Precision NanoSystems
- 20.14. Providence Therapeutics
- 20.15. Sanofi
- 20.16. Stemirna Therapeutics
- 20.17. Strand Therapeutic
- 20.18. Suzhou Abogen Bioscience
- 20.19. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF

PRICING DETAILS

Single-User Upto 2 Users - [PDF + Excel Only]

USD 4150

Multi-User Upto 10 Users - [PDF + Excel + PPT]

USD 5950

Enterprise-User Company-wide - [Report Pack + Benchmark + 6M Update]

USD 7750

Related Report

Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation